Among these studies, Latif et al. found that VIM was upregulated at both transcriptional and post-translational levels after the CIS treatment of metastatic epithelial ovarian tumor cells, increasing stemness and drug resistance (Latifi et al., 2011). The gene discussed is VIM; the disease is in situ carcinoma.